Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 19;3(Suppl 1):39-45.
doi: 10.1002/jha2.335. eCollection 2022 Jan.

Role of bridging therapy during chimeric antigen receptor T cell therapy

Shakthi T Bhaskar  1 , Bhagirathbhai R Dholaria  1 , Salyka M Sengsayadeth  1 , Bipin N Savani  1 , Olalekan O Oluwole  1
Affiliations
Review

Role of bridging therapy during chimeric antigen receptor T cell therapy

Shakthi T Bhaskar et al. EJHaem. .

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in clinical practice and have demonstrated excellent outcomes to those in clinical trials. However, increased real-world use of CAR T therapy has uncovered a number of barriers that can lead to significant delays in treatment. As a result, bridging therapy has become a widely used tool to stabilize or debulk disease between leukapheresis and CAR T cell administration. Here we review the available data regarding bridging therapy, with a focus on patient selection, choice of therapy, timing of therapy, and potential pitfalls.

Keywords: bridging therapy; chimeric antigen receptor T cell therapy; hematologic malignancies.

PubMed Disclaimer

Conflict of interest statement

STB, SMS and BNS report no COI. BRD reports institutional funding from Takeda, Janssen, Angiocrine, Pfizer, Poseida, MEI, Sorrento. Consultancy with Jazz, Celgene, Gamida Cell. OOO reports advisory board consultancy with Pfizer, Novartis, Janssen, Kite, Gilead, Spectrum, Bayer and Curio science. Research funding with Kite.

References

    1. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non‐hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20‐specific T cells. Blood. 2008;112(6):2261‐71. 10.1182/blood-2007-12-128843 - DOI - PMC - PubMed
    1. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73‐95ra73. 10.1126/scitranslmed.3002842 - DOI - PMC - PubMed
    1. Gökbuget N, Stanze D, Beck J, Diedrich H, Horst H‐A, Hüttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032‐41. 10.1182/blood-2011-12-399287 - DOI - PubMed
    1. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J‐M, Wei A, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836‐47. 10.1056/NEJMoa1609783 - DOI - PMC - PubMed
    1. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B‐cell lymphoma: Results from the international SCHOLAR‐1 study. Blood. 2017;130(16):1800‐8. 10.1182/blood-2017-03-769620 - DOI - PMC - PubMed

LinkOut - more resources